Physician profile
Mark Edward Velarde
NPI 1578513560
$9,692.16
in general payments reported to CMS, 2019-2025
45 companies · $1,283 in 2025
The $1,283 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,116 · 2020: $1,226 · 2021: $1,437 · 2022: $1,476 · 2023: $1,698 · 2024: $1,457 · 2025: $1,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,367 · Education: $70.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,367.27 |
| Education | $70.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,503.94 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,292.20 | 2021-2025 | Qulipta, Ubrelvy |
| Lilly USA, LLC | $1,283.09 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $982.39 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $621.91 | 2019-2025 | Jardiance, Tradjenta |
| Janssen Pharmaceuticals, INC | $492.58 | 2019-2022 | |
| Pfizer INC. | $461.30 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $348.58 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $310.60 | 2022-2025 | Xifaxan |
| Exact Sciences Corporation | $239.07 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Avanir Pharmaceuticals, INC. | $214.88 | 2019-2022 | |
| Glaxosmithkline, LLC. | $150.50 | 2022-2024 | Shingrix, Arexvy |
| Allergan, INC. | $142.45 | 2020 | |
| Amgen INC. | $139.16 | 2019-2025 | Evenity, Prolia |
| Amarin Pharma, INC. | $133.50 | 2020-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Velarde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.